Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 24th Preview)
-
FDA approvals in oncology
The FDA has approved lirafugratinib (Lyrfigtu) for adults with previously treated, unresectable or metastatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements, based on the REFOCUS phase 1/2 trial. The study included 116 patients and met its primary efficacy endpoints using RECIST v1.1, reporting a 46% objective response rate (ORR) and median duration of response (DOR) of 11.8 months. In parallel trial reporting, median progression-free survival was 11.3 months, with nearly half of patients progression-free at one year. The FDA decision also comes with safety label warnings characteristic of FGFR inhibition, including ocular toxicity, hyperphosphatemia and embryo-fetal toxicity. For biotech and pharma teams focused on molecularly defined oncology, the approval underscores regulators’ continued reliance on biomarker-selected cohorts and durable response metrics in small, single-group trials for hard-to-treat cancers.
-
FDA actions in diabetes care
Eli Lilly’s once-weekly basal insulin pen, Onswik, received FDA approval for patients with type 2 diabetes, setting up direct competition with Novo Nordisk. Lilly positioned the therapy as a longer-acting alternative to daily basal injections, aiming to simplify dosing for chronic glycemic control. The approval adds another practical dosing option for payers and clinicians, while raising competitive stakes for manufacturers already contesting long-acting insulin utilization and formulary placement. The move also signals ongoing regulatory comfort with incremental advances framed around convenience and pharmacologic duration. For biotech watchers, the decision highlights how next-generation insulin delivery—once-weekly regimens—remains a key battleground in established metabolic franchises.
-
Ophthalmology drug momentum after Merck deal
Merck’s ophthalmology effort tied to its $1.3 billion upfront acquisition of EyeBio has hit a pivotal milestone, according to the company’s first reported success. The development suggests the acquired platform is beginning to generate clinical signal after years of execution and portfolio buildout beyond Keytruda. The update matters for investors tracking Big Pharma’s risk calculus in specialty eye disease, where development timelines and endpoint selection can quickly determine whether external bets translate into differentiated products. Overall, Merck’s progress provides a datapoint for how late-stage validation can emerge from platform-centric licensing and acquisitions in ophthalmology.
-
Cell therapy long-term efficacy and FDA readiness
Kyverna Therapeutics reported one-year data supporting its autoimmune CAR-T submission for stiff person syndrome, with the company presenting long-term autoimmune benefit in the ongoing development effort. The condition affects an estimated 6,000 patients in the U.S., according to the company’s update. The company’s messaging emphasizes durability alongside a safety profile designed to address concerns that have slowed autoimmune CAR-T programs elsewhere in the category. While CAR-T therapy has established efficacy in oncology, autoimmune indications remain a higher bar due to relapse dynamics and immune safety risk. For the field, the read-through is that FDA submissions for autoimmune CAR-T will increasingly lean on sustained clinical benefit signals, not just early response.
-
Alzheimer’s: Phase 2 failure prompting Phase 3 changes
Acadia Pharmaceuticals reported a Phase 2 failure in Alzheimer’s disease psychosis but said the company has enough signal to continue into Phase 3 with modifications. The company framed the decision as a path forward after identifying activity signal despite missing the primary endpoint. For trials in psychiatric symptoms associated with neurodegeneration, this kind of outcome typically forces protocol renegotiations around enrichment, endpoint selection, and dose or duration. Analysts also highlighted debate on the safety language in the readout, which can influence confidence in the risk-benefit profile as development moves into a larger, longer Phase 3. The update reinforces how quickly Alzheimer’s development programs must adapt after mid-stage readouts in order to protect timelines and investor expectations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.